Yingzhong Li
President SunVax mRNA Therapeutics
Yingzhong Li earned his Ph.D. on Biotechnology from Peking University & National Institute of Biological Sciences, Beijing, China in 2010. Dr. Li got further trainings on multiple disciplines and interdisciplinary at MIT. Currently Dr. Li holds 6 PCT patents at MIT and 5 PCT patents at SunVax mRNA Therapeutics in the field of cancer immunology and mRNA techniques. Dr. Li is President of SunVax mRNA Therapeutics Inc. after left MIT in the end of 2021.
Seminars
Tuesday 21st July 2026
Cell-Type-Specific Delivery Beyond In Vivo CAR-T
4:45 pm
- Ionizable lipids suitable for cell type specific delivery
- Delivery efficacies beyond LNP
- Applications of cell-type-specific delivery beyond in vivo CAR-T
